Vincerx Pharma presents preclinical data on SMDCs at AACR

Vincerx Pharma announced that it presented a poster of preclinical data on novel integrin alphavbeta3-targeted small molecule drug conjugates, or SMDCs, at the American Association for Cancer Research, or AACR, Annual Meeting. "The preclinical data presented at AACR demonstrate our ability to synthesize and characterize novel SMDCs. The data showed high elastase-dependent potency and cytotoxicity across several cancer cell lines. Furthermore, the data demonstrate excellent plasma stability in rats with low plasma clearance from several alphavbeta3 conjugates. Based on these results, the large scope of potential payloads and tolerated conjugation chemistries gives rise to a versatile strategy for selective delivery of payloads to the tumor microenvironment that does not require the tumor target to internalize. Furthermore, these encouraging results demonstrate the extensive scientific expertise of the Vincerx team and our commitment to discovering and developing paradigm-shifting conjugates for patients with cancer. We are excited about the potential expansion of our bioconjugation platform and continue to evaluate linker variations with in vivo studies across different payload classes," said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx.